ADARB1 Antibody (OAAF02345)

Catalog No: OAAF02345 (Formerly GWB-ASD586)

Size:100 ug

Western blot analysis of extracts from HepG2 cells, using ADARB1 Antibody. The lane on the right is treated with the synthesized peptide.

Product Info

• Predicted Species Reactivity: Human|Mouse|Rat
• Product Format: Liquid PBS (without Mg²⁺ and Ca²⁺) (pH 7.4), 150mM NaCl, 0.02% sodium azide and 50% glycerol
• Clonality: Polyclonal
• Isotype: IgG
• Host: Rabbit
• Application: Enzyme-linked immunosorbent assay|Immunofluorescence|Immunohistochemistry|Immunohistochemistry-Paraffin|Western blot
• Reconstitution and Storage: -20°C
• Immunogen: The antiserum was produced against synthesized peptide derived from human ADARB1.
• Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
• Concentration: 1 mg/ml
• Specificity: ADARB1 antibody detects endogenous levels of total ADARB1 protein.
• Dilution: The optimal working dilution should be determined by the end user.
• Application Info: WB: 1:500~1000
  ELISA: 1:20000
• Reference: Mittaz L., Genomics 41:210-217(1997).
  Lai F., Mol. Cell. Biol. 17:2413-2424(1997).
  Villard L., Somat. Cell Mol. Genet. 23:135-145(1997).
• Description:
  View product citations for ADARB1 Antibody (OAAF02345) on CiteAb

Target Info

• Gene Symbol: ADARB1
• Gene Full Name: adenosine deaminase RNA specific B1
• Alias Symbols: ADAR2;adenosine deaminase, RNA-specific, B1 (homolog of rat RED1);double-stranded RNA-specific editase 1;DRABA2;DRADA2;dsRNA adenosine deaminase;dsRNA adenosine deaminase DRADA2;NEDHYMS;RED1;RNA editing deaminase 1;RNA-editing deaminase 1;RNA-editing enzyme 1.
• NCBI Gene Id: 104
• Protein Name: Double-stranded RNA-specific editase 1
• Description of Target: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis.
• Uniprot ID: P78563
• Protein Accession #: NP_001103.1
• Molecular Weight: 80 kDa